Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(11):861-862; doi:10.1093/jnci/94.11.861-a
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Parker, C.
Right arrow Articles by Dearnaley, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parker, C.
Right arrow Articles by Dearnaley, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 11, 861-862, June 5, 2002
© 2002 Oxford University Press

CORRESPONDENCE

Re: All-Cause Mortality in Randomized Trials of Cancer Screening

Chris Parker, David Dearnaley

Affiliation of authors: C. Parker, D. Dearnaley, Academic Radiotherapy Department, Royal Marsden Hospital, Surrey, U.K.

Correspondence to: Chris Parker, M.D., Academic Radiotherapy Department, Royal Marsden Hospital, Downs Rd., Sutton, Surrey, U.K. SM2 5PT (e-mail: cparker@icr.ac.uk).

We agree with Juffs and Tannock that "Screening trials are even more difficult than we thought they were" (1). We would add that the problem of slippery-linkage bias is not unique to screening trials and that adjuvant therapy trials may also be more difficult than we thought they were.

Consider, for example, the question of the optimum duration of adjuvant androgen deprivation in the treatment of prostate . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?